加码布局中国市场，阿斯利康本届进博会首发多款创新药

Core Insights - The eighth China International Import Expo opened in Shanghai on November 5, with AstraZeneca participating for the eighth consecutive year, showcasing its commitment to health in China and announcing an expansion of its production base in Qingdao [2] Group 1: New Drug Launch - AstraZeneca showcased two newly approved oncology drugs, QianKede® (Capecitabine Tablets) and Dazhuoyou® (Injection of Dazibotamab), at the expo, aimed at serving nearly 3.8 million patients in China [3] - Over the past seven years, the company has introduced 18 products in China, covering various therapeutic areas including respiratory, renal, digestive, rare diseases, autoimmune, and oncology [3] - The Beijing Global Strategic R&D Center was inaugurated in October, part of a $2.5 billion investment plan to accelerate the translation of innovative results into clinical drugs [3] Group 2: Production Expansion and Sustainability - On the first day of the expo, AstraZeneca signed an agreement with the Qingdao High-tech Zone Management Committee to invest approximately $136 million to expand its production base in Qingdao, enhancing the capacity for inhalation aerosol products to meet the needs of asthma and COPD patients [5] - The expansion project will incorporate energy-saving technologies with the goal of achieving near-zero carbon operations [5] - The company highlighted its three major bases in Wuxi, Taizhou, and Qingdao, with Wuxi achieving 100% renewable energy usage and carbon neutrality certification, and Taizhou reducing carbon emissions by 97.5% compared to 2015 [5][7]